论文部分内容阅读
目的探讨前列地尔联合贝那普利在糖尿病肾病蛋白尿治疗中的临床治疗效果。方法收集2012年1月—2014年12月收治的糖尿病肾病蛋白尿患者,选择具有可比性的80例作为研究对象,随机分成观察组与对照组各40例,对照组患者给予常规的胰岛素降糖、降压以及抗凝治疗,观察组患者在对照组治疗的基础上再给予前列地尔联合贝那普利治疗,分别对比两组患者治疗前后的24h尿蛋白含量、24h尿微量白蛋白排泄率以及治疗后的不良反应。结果治疗前两组患者的24h尿蛋白含量及24h尿微量白蛋白排泄率差异不明显(P>0.05),治疗后观察组患者的24h尿蛋白含量及24h尿微量白蛋白排泄率明显低于对照组,差异具有统计学意义(P<0.05),同时两组患者均未出现严重的不良反应。结论前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果显著,且治疗后不良反应发生率低,值得临床推广及应用。
Objective To investigate the clinical efficacy of alprostadil in combination with benazepril in the treatment of diabetic nephropathy. Methods 80 diabetic patients with diabetic nephropathy who were admitted to our hospital from January 2012 to December 2014 were enrolled in this study. Eighty patients with comparable proteinuria were randomly divided into observation group (40 cases) and control group (40 cases). Patients in control group , Antihypertensive and anticoagulant therapy. Patients in the observation group were treated with alprostadil plus benazepril on the basis of the control group. The levels of 24-hour urinary protein and 24-hour urinary albumin excretion were compared between the two groups before and after treatment As well as the adverse reactions after treatment. Results There was no significant difference in 24h urinary protein content and 24h urinary albumin excretion rate between the two groups before treatment (P> 0.05). After treatment, the urinary albumin excretion rate of 24h group and 24h urinary albumin excretion rate were significantly lower than those of the control group Group, the difference was statistically significant (P <0.05), while no serious adverse reactions in both groups. Conclusion Alprostadil combined with benazepril treatment of diabetic nephropathy proteinuria clinical effect is significant, and the incidence of adverse reactions after treatment is low, worthy of clinical promotion and application.